[Butoconazole nitrate in vulvovaginal candidiasis. A comparative study with clotrimazole]. 1988

E Herrera Nava, and R Bervera Castañeda, and S Escalona, and M Gutiérrez, and G Zamora López

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002181 Candidiasis, Vulvovaginal Infection of the VULVA and VAGINA with a fungus of the genus CANDIDA. Moniliasis, Vulvovaginal,Vaginitis, Monilial,Candidiasis, Genital,Genital Vulvovaginal Candidiasis,Vaginal Yeast Infection,Vaginal Yeast Infections,Candidiasis, Genital Vulvovaginal,Genital Candidiasis,Infection, Vaginal Yeast,Infections, Vaginal Yeast,Monilial Vaginitis,Vulvovaginal Candidiasis,Vulvovaginal Candidiasis, Genital,Vulvovaginal Moniliasis,Yeast Infection, Vaginal,Yeast Infections, Vaginal
D003022 Clotrimazole An imidazole derivative with a broad spectrum of antimycotic activity. It inhibits biosynthesis of the sterol ergostol, an important component of fungal CELL MEMBRANES. Its action leads to increased membrane permeability and apparent disruption of enzyme systems bound to the membrane. Bay b 5097,Canesten,FB b 5097,Kanesten,Klotrimazole,Lotrimin,Mycelex
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics

Related Publications

E Herrera Nava, and R Bervera Castañeda, and S Escalona, and M Gutiérrez, and G Zamora López
October 1984, Obstetrics and gynecology,
E Herrera Nava, and R Bervera Castañeda, and S Escalona, and M Gutiérrez, and G Zamora López
July 1986, The Medical letter on drugs and therapeutics,
E Herrera Nava, and R Bervera Castañeda, and S Escalona, and M Gutiérrez, and G Zamora López
January 1990, The Journal of international medical research,
E Herrera Nava, and R Bervera Castañeda, and S Escalona, and M Gutiérrez, and G Zamora López
November 1986, The Journal of reproductive medicine,
E Herrera Nava, and R Bervera Castañeda, and S Escalona, and M Gutiérrez, and G Zamora López
January 1978, Acta obstetricia et gynecologica Scandinavica,
E Herrera Nava, and R Bervera Castañeda, and S Escalona, and M Gutiérrez, and G Zamora López
June 1991, DICP : the annals of pharmacotherapy,
E Herrera Nava, and R Bervera Castañeda, and S Escalona, and M Gutiérrez, and G Zamora López
January 1996, Infectious diseases in obstetrics and gynecology,
E Herrera Nava, and R Bervera Castañeda, and S Escalona, and M Gutiérrez, and G Zamora López
January 1995, Sexually transmitted diseases,
E Herrera Nava, and R Bervera Castañeda, and S Escalona, and M Gutiérrez, and G Zamora López
February 1986, The Journal of reproductive medicine,
E Herrera Nava, and R Bervera Castañeda, and S Escalona, and M Gutiérrez, and G Zamora López
January 1977, La Prensa medica mexicana,
Copied contents to your clipboard!